NCT04892641View on ClinicalTrials.gov

Phase 1 Study of Epetraborole Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 10, 2021

Primary Completion Date

February 26, 2022

Study Completion Date

February 26, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

Epetraborole

Epetraborole hydrochloride 250 mg tablets for oral administration

DRUG

Placebo

Matching placebo for 250 mg epetraborole hydrochloride tablets for oral administration

Trial Locations (1)

5000

CMAX Clinical Research, Adelaide

Sponsors
All Listed Sponsors
lead

AN2 Therapeutics, Inc

INDUSTRY